Strikingly, optimized lung targeting LNPs (DOTAP40) could transfect ~60% of the lung basal cell population after systemic IV administration, which is very promising for CF therapy as sufficient CFTR gene correction in lung basal cells could contribute to long-term functional restoration of the airway epithelium. The gene discussed is CFTR; the disease is cystic fibrosis.